How a new CEO has been trying to position Editas to execute on the promise of CRISPR
Gilmore O’Neill is working to inject stability and focus at Editas as the company aims to execute on both ex-vivo and in-vivo crispr gene therapies.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
Popular
#1. Pfizer’s CEO on Q2 earnings.
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square
bottom of page